Status:
COMPLETED
Patient-derived Organoids Drug Screen in Pancreatic Cancer
Lead Sponsor:
Prof. Dr. med. Dres. h.c. Jan Schmidt, MME
Conditions:
Pancreas Cancer
Pancreas Neoplasm
Eligibility:
All Genders
18-100 years
Phase:
NA
Brief Summary
Few chemotherapeutic options exist for pancreatic cancer. Moreover, objective criteria are lacking for deciding which regimen is more beneficial for patient presenting with metastases at diagnosis. T...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Written informed consent provided
- Patients older than 18 years
- Histologically- or cytologically-proven pancreatic ductal adenocarcinoma (PDAC)
- Tumour lesion amenable for laparoscopic, surgical biopsy
- Eastern Cooperative Oncology Group (ECOG) Performance status (PS) 0-2
- Radiologically measurable disease
- Life expectancy \> 3 months
- Absolute neutrophile count \>1500/microL, platelets \>100'000/microL
- Serum creatinine \<1.5 times of the upper limit of normal or Clearance \>50ml/min (according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula)
- Exclusion criteria:
- Concomitant need for full anticoagulation that cannot be interrupted or bridged prior to tissue biopsy
- ECOG PS \>2
- Heart failure (NYHA class III-IV)
- Severe or uncontrolled concurrent illness
- Myocardial infarction within the previous 6 months
Exclusion
Key Trial Info
Start Date :
September 22 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05351983
Start Date
September 22 2022
End Date
December 31 2023
Last Update
September 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hirslanden Kliniks
Zurich, Canton of Zurich, Switzerland, 8002